Compounded Tirzepatide: What Changed and Why It Mostly Ended

Compounded tirzepatide existed because of a shortage, and it largely stopped existing when the shortage resolved. That single sentence explains most of what people find confusing about the category — including why something that was widely advertised as legal became something else.

Why compounding was permitted at all

Compounding pharmacies prepare customised medicines for individual patients. Ordinarily they may not simply reproduce a commercially available approved drug — that would undercut the approval system entirely.

A drug on FDA’s shortage list is the exception. While a product is listed as in shortage, compounders may prepare copies of it, because the alternative is patients going without. That exception is what the entire compounded tirzepatide market was built on.

503A versus 503B

These are meaningfully different tiers, and marketing rarely distinguishes them. A 503B outsourcing facility operates under considerably more oversight than a 503A pharmacy. Neither produces an FDA-approved product — compounded drugs are not approved, by definition.

What compounded is not

• Not a generic. A generic is an approved product proven bioequivalent to the reference drug. Tirzepatide is under patent; no generic exists.

• Not FDA approved. Compounded drugs are exempt from approval requirements, not approved. This is the most commonly blurred point.

• Not necessarily the same formulation. Compounded versions have appeared with different salt forms, different concentrations and added ingredients such as vitamins — none of which was in the trials.

• Not covered by the manufacturer’s safety monitoring. Adverse events with a compounded product do not flow into the approved product’s pharmacovigilance.

Where things stand

The "personalised dose" argument deserves scrutiny. Some sellers now offer doses that differ slightly from the approved strengths, arguing this makes the product a genuine compounded preparation rather than a copy. Whether that satisfies the law is contested, and it is not a determination a buyer can make from a website.

Why price differences persist

Compounded products were dramatically cheaper, and that gap drove the market. It reflected the absence of the costs that sit behind an approved product — trials, manufacturing validation, pharmacovigilance, regulatory affairs — rather than a more efficient way of making the same thing.

For what the research-chemical channel charges, see the peptide cost guide and the vendor comparison.

Questions worth asking

1. Is this a 503A pharmacy or a 503B outsourcing facility?

2. Is the active ingredient tirzepatide base, or a salt form?

3. What else is in the vial? Added B12 or other ingredients were common and were not in any trial.

4. What is the concentration? It frequently differs from the approved product, which changes every dose calculation.

5. Who prescribed it, and did they see a full history?

The grey market guide covers the research-use-only channel, and the FDA-approved peptides list covers what approval actually means.